Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac markers: centralized or decentralized testing?

M Plebani1, M Zaninotto

  • 1Department of Laboratory Medicine, University Hospital, Padova, Italy. pad08821@pd.nettuno.it

Clinical Chemistry and Laboratory Medicine
|March 22, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurofilament light chain and profilin-1 dynamics in 30 spinal muscular atrophy type 3 patients treated with nusinersen.

European journal of neurology·2024
Same author

Hook-effect in MAGLUMI immunoassay for serum anti-GAD antibodies in neurological disorders: When "wrong" matrix is the right choice.

Clinica chimica acta; international journal of clinical chemistry·2024
Same author

Vitamin K in CKD Bone Disorders.

Calcified tissue international·2021
Same author

SARS-CoV-2 containment in complex surgical units during the COVID-19 pandemic.

The British journal of surgery·2020
Same author

Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation.

Journal of endocrinological investigation·2020
Same author

Bone turnover markers, BMD and TBS after short-term, high-dose glucocorticoid therapy in patients with Graves' orbitopathy: a small prospective pilot study.

Journal of endocrinological investigation·2018
Same journal

Ethical evaluation of reflex and reflective testing in conformity with ISO 15189:2022 at the value-based laboratory medicine era.

Clinical chemistry and laboratory medicine·2026
Same journal

Emerging blood-based diagnostic strategies for tuberculosis.

Clinical chemistry and laboratory medicine·2026
Same journal

Homocitrulline and 3-year mortality in older hospitalised adults: an exploratory study.

Clinical chemistry and laboratory medicine·2026
Same journal

Impact of age partitioning on classification discordance in pediatric ferritin reference intervals.

Clinical chemistry and laboratory medicine·2026
Same journal

National implementation of LOINC: translation methodology and experience from the Polish laboratory terminology standardization project.

Clinical chemistry and laboratory medicine·2026
Same journal

Harmonization of measurement units: mission impossible or ethical imperative?

Clinical chemistry and laboratory medicine·2026
See all related articles

New quantitative near-patient testing devices offer a viable alternative for diagnosing acute coronary syndrome, improving upon traditional methods and qualitative bedside tests for cardiac markers.

Area of Science:

  • Clinical Chemistry
  • Cardiovascular Diagnostics
  • Point-of-Care Testing

Background:

  • Traditional enzymatic assays for acute myocardial infarction are being replaced by more sensitive cardiac markers like troponins.
  • The clinical utility of new cardiac markers raises questions about assay strategies, specimen handling, and turnaround times.

Purpose of the Study:

  • To review the evolving landscape of cardiac marker testing for acute coronary syndrome.
  • To evaluate near-patient testing (NPT) devices as an alternative to traditional laboratory methods.
  • To discuss regulatory and quality management aspects of decentralized cardiac marker testing.

Main Methods:

  • Review of current literature on cardiac marker assays and NPT devices.
  • Analysis of the performance and limitations of qualitative and quantitative NPT devices.

Related Experiment Videos

  • Discussion of regulatory and quality assurance considerations for NPT.

    • Main Results:

    • Quantitative NPT devices show promise as a decentralized testing alternative.
    • Qualitative bedside tests for cardiac markers have limitations impacting clinical usefulness.
    • Emerging NPT technologies require careful consideration of performance and regulatory compliance.

    Conclusions:

    • Quantitative near-patient testing represents a significant advancement in diagnosing acute coronary syndrome.
    • Careful selection and validation of NPT devices are crucial for clinical adoption.
    • Decentralized testing strategies necessitate robust quality management and regulatory oversight.